NCT00240019View on ClinicalTrials.gov

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

April 30, 2006

Conditions
Diabetic Nephropathy
Interventions
DRUG

Addition of furosemide 20 mg oral bid to baseline regimen

Trial Locations (2)

94305

Stanford University Medical Center, Stanford

95051

Kaiser Permanente of Northern California, Santa Clara and San Jose, Santa Clara

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Stanford University

OTHER

NCT00240019 - Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease. | Biotech Hunter | Biotech Hunter